Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Nov;32 Suppl 2(Suppl 2):S237-45.
doi: 10.2337/dc09-S355.

Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration

Bart Staels  1 , Vivian A Fonseca
Affiliations
Review

Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration

Bart Staels et al. Diabetes Care. 2009 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of the impact of FXR on lipid metabolism. FXR activation by bile acids induces the expression of sterol regulatory element–binding protein-1c (SREBP1c) in mice and peroxisome proliferator–activated receptor-α (PPARα) in humans, which both will modulate triglyceride (TG) production. However, the increase of apoC-II, VLDL receptor, and syndecan 1 gene expression together with the repression of apoC-III will increase LPL activity and therefore triglyceride clearance. FXR also represses apoAI expression and therefore HDL levels but also enhances the remodeling of HDL particles by induction of phospholipid transfer protein (PLTP) and perhaps cholesteryl ester transfer protein (CETP) expression. Used with permission from Claudel et al. (10).
See this image and copyright information in PMC

References

    1. Insull W, Jr: Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99: 257– 273 - PubMed
    1. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B: Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147– 191 - PubMed
    1. Houten SM, Watanabe M, Auwerx J: Endocrine function of bile acids. EMBO J 2006; 25: 1419– 1425 - PMC - PubMed
    1. Garg A, Grundy SM: Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus: a short-term, double-blind, crossover trial. Ann Intern Med 1994; 121: 416– 422 - PubMed
    1. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL: Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycaemic control in subjects with type 2 diabetes. Clin Ther 2007; 29: 74– 83 - PubMed

Publication types